Loading...
01/10 06:04
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture. Financial performance shows some positive aspects, like EBITDA growth and debt reduction, but net sales decline and operational cost concerns weigh negatively. The Q&A reveals cautious sentiment, especially with unclear guidance on Protocol's ROI and North America's performance. While shareholder returns and debt management are promising, market variability and weak guidance temper the outlook. Given the lack of a strong catalyst and balanced positive and negative factors, a neutral sentiment is justified for the stock price movement.
Net Sales $1,200,000,000, down 3.4% year-over-year; impacted by a negative FX headwind of approximately 480 basis points, but on a constant currency basis, net sales grew by 1.4%.
Adjusted EBITDA $165,000,000, up 19% year-over-year; driven by cost savings initiatives implemented in 2024, with adjusted EBITDA margins at 13.5%, up 260 basis points.
Gross Profit Margin 78.3%, up 80 basis points year-over-year; primarily due to pricing actions and reduced input costs, partially offset by higher inventory write-downs.
Net Income $50,000,000; includes approximately $5,000,000 of non-cash net deferred income tax related to a deferred income tax benefit recognized in Q4 2024.
Adjusted Diluted EPS $0.59, includes a $0.13 FX headwind year-over-year.
Operating Cash Flows Neutral for Q1; impacted by annual distributor bonuses of approximately $74,000,000 and employee performance bonuses of about $35,000,000, which were higher than last year.
Debt Repayment Approximately $70,000,000 repaid during the quarter, including $65,000,000 of the 2025 notes redeemed in February.
Total Leverage Ratio Reduced to 3 times as of March 31, achieving the target set to be reached by the end of 2025, nine months ahead of plan.
Cash Balance $329,000,000 as of March 31; reflects optimization of cash management.
Capital Expenditures (CapEx) $18,000,000, significantly below the guidance range of $30,000,000 to $40,000,000 due to delays and reprioritization of certain projects.
New Product Launches: Herbalife plans to launch a beta version of the Protocol platform in July 2025, with a commercial release in the U.S. planned for Q4 2025. This platform will provide personalized nutrition recommendations and lifestyle plans.
Product Portfolio Expansion: The acquisition of Protocol will allow Herbalife to expand its product offerings with protocol-specific products, enhancing customer engagement and driving growth.
Acquisition of Pruvit Ventures: Herbalife acquired Pruvit Ventures, a direct seller of patented ketone supplements, which will allow Herbalife to enter a new product category.
Market Expansion: Herbalife's new acquisitions, including Protocol Health, Pruvit Ventures, and Link Biosciences, are expected to enhance its market positioning in the health and wellness sector.
Distributor Growth: The number of new distributors joining Herbalife worldwide increased by 16% year over year, marking the fourth consecutive quarter of new distributor growth.
Operational Efficiency: Herbalife reduced its total leverage ratio to 3.0 times as of March 31, 2025, achieving this milestone nine months ahead of plan.
Cost Savings Initiatives: Adjusted EBITDA for Q1 was $165 million, exceeding guidance, primarily driven by cost savings initiatives implemented in 2024.
Strategic Shift: Herbalife is transitioning to a more technology-driven approach, focusing on AI-powered solutions and personalized health and wellness programs.
Leadership Transition: Stefan Graziani has transitioned to the role of CEO, emphasizing a commitment to evolving Herbalife's mission and leveraging technology for growth.
Net Sales Performance: Net sales of $1,200,000,000 were down 3.4% compared to Q1 of 2024, with a significant negative impact from foreign exchange (FX) rates, which had a $60,000,000 headwind.
Competitive Pressures: The company faces increasing competition in the health and wellness market, necessitating a focus on innovation and personalized offerings to maintain market position.
Regulatory Issues: The company anticipates some impact from newly enacted tariffs, although it is not expected to be material to overall results.
Supply Chain Challenges: There are challenges related to sourcing ingredients from China, which could be impacted by tariffs, but the overall effect is deemed manageable.
Economic Factors: The current economic environment may influence consumer behavior, with potential for increased interest in direct selling opportunities as individuals seek additional income.
Debt Management: The company is focused on reducing its debt, having achieved a total leverage ratio of three times, but ongoing debt repayment remains a priority.
Operational Costs: Increased operational costs associated with the launch of new technology and acquisitions may impact short-term profitability.
Market Variability: Regional performance varies, with some markets like North America and China showing weakness, while others like Latin America and Asia Pacific demonstrate growth.
Acquisitions: Herbalife announced the acquisition of Protocol Health, Pruvit Ventures, and Link Biosciences, which are expected to enhance their product offerings and technology capabilities.
Innovation Focus: The company is focusing on innovation in products, technology, and AI-powered solutions to empower distributors and better serve customers.
Distributor Engagement Programs: Herbalife is implementing programs to strengthen its distributor base, including the Herbalife Premier League and the Flex45 Challenge.
New Technology Platform: The launch of the Protocol platform aims to provide personalized health recommendations and improve distributor-customer engagement.
Q1 Net Sales: Net sales for Q1 were $1.2 billion, down 3.4% year-over-year, but up 1.4% on a constant currency basis.
Q2 Guidance: For Q2, net sales are expected to range from down 3.5% to up 0.5% year-over-year, with adjusted EBITDA guidance of $160 million to $170 million.
Full Year Guidance: For the full year 2025, net sales are expected to range from down 2.5% to up 2.5%, with adjusted EBITDA raised to a range of $625 million to $655 million.
CapEx Guidance: Capital expenditures for the year are now expected to be in the range of $90 million to $120 million.
Shareholder Return Plan: Herbalife announced a significant step in its shareholder return strategy through a debt repayment of approximately $70,000,000 during the first quarter, which included the redemption of $65,000,000 of 2025 notes. The company has successfully reduced its total leverage ratio to three times as of March 31, achieving this milestone nine months ahead of plan. Additionally, the company is committed to reducing its principal amount of debt outstanding to $1,400,000,000 by the end of 2028, which represents a billion dollar reduction from its previous debt levels.
The company has shown positive financial performance with debt reduction, regional sales growth, and promising product launches. The Q&A session highlighted strong engagement and feedback for new products, with no anticipated increase in SG&A costs. The raised guidance and strategic focus on subscription revenue and new product lines further support a positive outlook. Despite some lack of detail on profitability differences, overall market sentiment appears optimistic, suggesting a positive stock price movement.
The earnings call reveals mixed signals: while financial metrics and guidance are stable, regional performance shows declines, and management's clarity on future strategies, particularly regarding Pro2col, is lacking. The Q&A highlights uncertainties about monetization and global rollout, which might concern investors. The market's response is likely neutral due to these offsetting factors.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
